share_log

HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $15 Price Target

HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $15 Price Target

HC Wainwright & Co.重申买入加的夫肿瘤学,维持15美元的目标价格
Benzinga ·  2023/03/29 06:48

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $15 price target.

HC Wainwright & Co. 分析师Raghuram Selvaraju重申了加的夫肿瘤学(纳斯达克股票代码:CRDF)的买入,并维持15美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发